Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionSG Americas Securities, LLC
Latest Disclosed Ownership55,060 shares
Latest Disclosed Value $ 18,218
SG Americas Securities, LLC ownership in DUL / Alnylam Pharmaceuticals, Inc.

On April 16, 2026 - SG Americas Securities, LLC filed a 13F-HR form disclosing ownership of 55,060 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $15,730,642 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 9, 2026 disclosing 90,921 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -39.44% during the quarter. The current value of the position is $14,343,130 USD.

SG Americas Securities, LLC has a history of taking positions in derivatives of the underlying security (DUL) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:DUL / Alnylam Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-16 2026-03-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 55,060 -35,861 -39.44 18 -50.00 0.0196
2026-01-09 2025-12-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 90,921 59,071 185.47 36 157.14 0.0462
2025-10-23 2025-09-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 31,850 31,850 15 0.0490
2025-08-08 2025-06-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 0 -132,960 -100.00 0 -100.00
2025-04-15 2025-03-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 132,960 131,293 7,876.00 36 0.1178
2025-01-17 2024-12-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 1,667 -1,723 -50.83 0 0.0016
2024-10-03 2024-09-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 3,390 2,953 675.74 1 0.0034
2024-07-12 2024-06-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 437 -38,318 -98.87 0 -100.00 0.0006
2024-05-06 2024-03-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 38,755 38,095 5,771.97 6 0.0279
2024-01-12 2023-12-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 660 -19,176 -96.67 0 -100.00 0.0012
2023-10-13 2023-09-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 19,836 16,025 420.49 4 0.0402
2023-07-10 2023-06-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 3,811 -7,883 -67.41 1 -100.00 0.0055
2023-04-28 2023-03-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 11,694 4,900 72.12 2 100.00 0.0272
2023-02-02 2022-12-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 6,794 5,575 457.34 2 -99.59 0.0197
2022-10-31 2022-09-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 1,219 -12,730 -91.26 244 -88.00 0.0030
2022-07-29 2022-06-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 13,949 -14,065 -50.21 2,034 -55.53 0.0217
2022-04-29 2022-03-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 28,014 19,168 216.69 4,574 204.93 0.0335
2022-02-07 2021-12-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 8,846 -2,041 -18.75 1,500 -27.04 0.0082
2021-11-01 2021-09-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 10,887 -8,185 -42.92 2,056 -36.41 0.0097
2021-08-12 2021-06-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 19,072 16,386 610.05 3,233 753.03 0.0150
2021-05-13 2021-03-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 2,686 401 17.55 379 27.61 0.0020
2021-02-04 2020-12-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 2,285 -919 -28.68 297 -36.40 0.0016
2020-11-09 2020-09-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 3,204 -10,553 -76.71 467 -77.09 0.0030
2020-07-20 2020-06-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 13,757 10,015 267.64 2,038 400.74 0.0170
2020-04-30 2020-03-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 3,742 499 15.39 407 9.12 0.0038
2020-01-28 2019-12-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 3,243 1,470 82.91 373 160.84 0.0034
2019-11-04 2019-09-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 1,773 1,773 143 0.0012
2019-07-29 2019-06-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 0 -133,828 -100.00 0 -100.00
2019-04-29 2019-03-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 133,828 114,143 579.85 12,506 771.50 0.1151
2019-01-31 2018-12-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 19,685 10,255 108.75 1,435 73.94 0.0125
2018-11-06 2018-09-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 9,430 4,652 97.36 825 75.16 0.0061
2018-08-07 2018-06-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 4,778 -18,108 -79.12 471 -82.72 0.0042
2018-05-03 2018-03-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 22,886 22,886 2,726 0.0218
2018-01-24 2017-12-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 0 -1,538 -100.00 0 -100.00
2017-11-07 2017-09-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 1,538 -105,643 -98.57 181 -97.88 0.0016
2017-08-03 2017-06-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 107,181 107,181 8,549 0.0770
2017-05-10 2017-03-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 0 -22,683 -100.00 0 -100.00
2017-02-08 2016-12-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 22,683 22,683 849 0.0071
2016-11-08 2016-09-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 0 -6,353 -100.00 0 -100.00
2016-08-03 2016-06-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 6,353 1,510 31.18 353 16.12 0.0025
2016-05-12 2016-03-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 4,843 993 25.79 304 -16.02 0.0022
2016-02-12 2015-12-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 3,850 -2,439 -38.78 362 -28.32 0.0026
2015-11-09 2015-09-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 6,289 -8,225 -56.67 505 -70.98 0.0030
2015-08-06 2015-06-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 14,514 10,165 233.73 1,740 283.26 0.0115
2015-05-13 2015-03-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 4,349 -12,497 -74.18 454 -72.22 0.0027
2015-02-12 2014-12-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 16,846 9,010 114.98 1,634 210.65 0.0080
2014-05-14 2014-03-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 7,836 7,836 -28.58 526 -25.07 0.0023
2014-02-12 2013-12-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 0 -10,971 -100.00 0 -100.00
2013-11-12 2013-09-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 10,971 10,971 702 0.0029
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2017-05-10 2017-03-31 13F ALNYLAM PHARMACEUTICALS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2017-02-08 2016-12-31 13F ALNYLAM PHARMACEUTICALS OPT Call 63,000 6 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2020-07-20 2020-06-30 13F ALNYLAM PHARMACEUTICALS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2020-04-30 2020-03-31 13F ALNYLAM PHARMACEUTICALS OPT Put 32,200 129 n/a n/a n/a
2018-08-07 2018-06-30 13F ALNYLAM PHARMACEUTICALS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2018-05-03 2018-03-31 13F ALNYLAM PHARMACEUTICALS OPT Put 22,900 225 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.